Jaythari is indicated for the treatment of DMD, a rare and genetic disease that results in ongoing muscle weakness and degeneration.

The drugmaker has received the USFDA's final approval to manufacture a particular corticosteroid called Deflazacort to treat Duchenne muscular dystrophy.

Reliance Industries, Tata Power, Sula Vineyards, NCL Industries, IRCON International, Ashoka Buildcon are some of the top ...

Stocks including HCL Technologies, IRCON International, Zydus Lifesciences, Tata Power, Cyient, Indian Hotels, JK Cement, Havells and Macrotech Developers will be in the spotlight on Tuesday, April 15 ...

Explore the latest stock alerts: Macrotech, Reliance, Vedanta, Dr Reddy's, and more. Check out key developments today!

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg (USRLD: Emflaza ...